übergewichtige und adipöse Patienten mit arterieller Hypertonie : Wirksamkeit und Verträglichkeit von Irbesartan als Monotherapie oder in Kombination mit Hydrochlorothiazid

摘要: Background and aims: Obese patients often present with arterial hypertension that is difficult to control. Under pathophysiological aspects treatment AT 1 receptor blockers a rational option. Thus, we investigatedthe efficacy safety of irbesartan in daily doses 75-300 mg as monotherapy, or combination the diuretic hydrochlorothiazide (HCT) 12.5 mg/d, respectively, an unselected patient sample primary care setting. Methods: Between February September 2004 to-tal 72,479 were included by 6,989 physicians open, prospective 3-month trial. Primary criterion was decrease ofsystolic diastolic blood pressure (SBP/ DBP) after 3 months, number adverse drugs reactions (ADR). Results: Patients had mean age 62 years, male 50%, 92.3% overweight obese (mean body mass index 30.7 ′ 4.8 kg/m 2 ). 71% treated irbesartan/HCT 150/12.5 mg/d 300/12.5 combinations, 22% 300 mg/d. Mean SBP/DBP at study end 23.2/11.7 mmHg. There no differences BP response between normal weight patients. Concomitant albuminuria reduced 74% metabolic parameters improved during study. ADR occurred 0.4%. Conclusion: therapy, experience significant elevated BP. Considering excellent tolerability, favourable effects, known organ protective properties, useful this group monotherapy HCT.